@Umizoomi
Let me see if it is possible to explain my viewpoint more clearly.
There are multiple pieces of information that will factor into the future probability of sufficient return on investment.
Each piece serves to influence the probability or risk factor.
A cumulative risk approach, takes into account as many sources of information as relevant.
These indications of probability as discussed in previous posts, when factored into the tiny market cap, relative, to the value of a successful product, provide a measure of confidence I would like to see in other biopharma, yet don't. This provides a competitive edge for the future stock price.
shaken, not stirred., page-12
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
-0.001(7.14%) |
Mkt cap ! $13.37M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.7¢ | 0.6¢ | $264 | 42.41K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 6055648 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 1726391 | 6 |
View Market Depth
| Last trade - 14.46pm 22/07/2024 (20 minute delay) ? |
| PAB (ASX) Chart |